CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Q38355000)

2 September 2017

title

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (English)

1 reference

2 September 2017

A Takeshita

1

1 reference

2 September 2017

N Yamakage

2

1 reference

2 September 2017

K Shinjo

3

1 reference

2 September 2017

T Ono

4

1 reference

2 September 2017

I Hirano

5

1 reference

2 September 2017

S Nakamura

6

1 reference

2 September 2017

K Shigeno

7

1 reference

2 September 2017

T Tobita

8

1 reference

2 September 2017

M Maekawa

9

1 reference

2 September 2017

H Kiyoi

10

1 reference

2 September 2017

T Naoe

11

1 reference

2 September 2017

K Ohnishi

12

1 reference

2 September 2017

Y Sugimoto

13

1 reference

2 September 2017

R Ohno

14

1 reference

2 September 2017

publication date

16 April 2009

1 reference

2 September 2017

1 reference

2 September 2017

volume

23

1 reference

2 September 2017

issue

7

1 reference

2 September 2017

page(s)

1329-1336

1 reference

Current trends in large cell lymphoma

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Rituximab therapy in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

How I treat refractory CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

CD20-positive adult T-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Difference in CD22 molecules in human B cells and basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

A green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Pathogenesis of cardiotoxicity induced by anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

7 January 2021

Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

7 January 2021

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

7 January 2021

Monoclonal antibody therapy for B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.77

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.77

1 reference

Dimensions Publication ID

2 September 2017

1014229354

0 references

1 reference